LIDODERM (lidocaine) by Teikoku Seiyaku is clinical pharmacology pharmacodynamics lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Approved for postherpetic neuralgia. First approved in 1999.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
LIDODERM is a topical lidocaine 5% patch approved in 1999 for postherpetic neuralgia and other localized pain conditions. It works as an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting ionic fluxes required for pain signal initiation and conduction. The patch delivers minimal systemic absorption (3% of applied dose), making it a low-risk topical alternative to oral analgesics.
Product is approaching loss of exclusivity with minimal current Part D spending, indicating reduced commercial momentum and likely smaller brand team presence.
CLINICAL PHARMACOLOGY Pharmacodynamics Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of…
Worked on LIDODERM at Teikoku Seiyaku? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Amide Local Anesthetic
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Lidocaine for LESS Postoperative Shoulder Pain Alleviation
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine
LIDODERM shows no linked job openings in the dataset, reflecting its mature, low-spending commercial status ($3M Part D, 2215 claims). Career opportunities are limited to small brand teams focused on maintenance, managed care contracting, and generic transition management rather than growth or innovation.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo